top of page

New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.


Alzheimer’s Association International Conference 2016, Toronto, Canada

Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Anastasios Zografidis, Christopher U. Missling

View Poster

bottom of page